

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00455)

DELAY IN DESPATCH OF CIRCULAR AND GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES

Reference is made to the announcement of Tianda Pharmaceuticals Limited (the “**Company**”) dated 5 October 2020 (the “**Announcement**”) in relation to, among others, the Share Transfer and Cooperation Agreement entered into between the Purchaser and the Vendor. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular containing, among others, (i) further details of the Share Transfer and Cooperation Agreement; (ii) the financial information of the Group; (iii) the financial information of the Target Group; and (iv) the valuation report on the Property (the “**Circular**”) was expected to be despatched to the Shareholders on or before 27 October 2020.

As additional time is required for the Company to prepare and finalise the accountants’ report of the Target Group, pro forma statement of the assets and liabilities of the enlarged Group, the statement of indebtedness and the valuation report on the Property to be included in the Circular, the Company has applied to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules. As at the date of this announcement, the Stock Exchange has granted the aforesaid waiver to the Company and allows the despatch date of the Circular be postponed to a day falling on or before 24 November 2020.

For and on behalf of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 27 October 2020

As at the date of this announcement, the executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive Directors are Mr. SHEN Bo, Mr. FENG Quanming and Dr. LAM Lee G.; and the independent non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.